Is having lower blood pressure at the start of treatment linked to higher risk in stable CAD?
For people with stable coronary artery disease (CAD), managing blood pressure is a key part of treatment. However, the question of whether starting with lower blood pressure might actually increase risk has been raised by some research. A recent analysis of the AFIRE trial looked specifically at this question in patients who have both atrial fibrillation (AF) and stable CAD. The findings suggest that in this group, a lower systolic blood pressure at the start of treatment was associated with a higher risk of cardiovascular events and death 3. This does not mean that blood pressure should not be controlled, but it highlights that the optimal target may vary depending on other health conditions.
What the research says
A post-hoc analysis of the AFIRE trial examined 2,135 patients with atrial fibrillation and stable coronary artery disease 3. Researchers divided patients into two groups based on their systolic blood pressure (SBP) at the start of the study: a high SBP group (average 139 mmHg) and a low SBP group (average 114 mmHg) 3. After adjusting for other factors, the low SBP group had a significantly higher risk of the primary endpoint, which was a combination of cardiovascular events and death from any cause (hazard ratio 1.38; 95% CI 1.01-1.88; p=0.039) 3. This means the low SBP group had about a 38% higher risk compared to the high SBP group. The risk of major bleeding was similar between the two groups 3.
Importantly, this was a post-hoc analysis, meaning it was not the main planned analysis of the trial. The study also only included patients with both AF and stable CAD, so the results may not apply to everyone with stable CAD. The researchers noted that in the low SBP group, using rivaroxaban alone (without aspirin) was linked to lower risks of both the primary endpoint and bleeding, compared to using rivaroxaban plus an antiplatelet drug 3. This suggests that the type of blood thinner used might also matter.
Other sources in this set do not directly address the question of baseline blood pressure and risk. For example, one trial protocol for a Chinese herbal formula in stable CAD does not discuss blood pressure levels 1. A subgroup analysis of the MUST trial looked at a different traditional Chinese medicine in patients with reduced kidney function, but did not examine baseline blood pressure 2. A trial of colchicine in stable CAD focused on plaque changes, not blood pressure 4. Standard medical guidelines emphasize blood pressure control with medications like beta blockers and ACE inhibitors, but do not specify a lower limit that might be harmful 5.
What to ask your doctor
- What is my target blood pressure range given my specific health conditions, such as atrial fibrillation or kidney disease?
- If my systolic blood pressure is on the lower side (e.g., below 120 mmHg), should I be concerned about increased cardiovascular risk?
- Does my current blood pressure medication regimen need adjustment based on my baseline blood pressure and other risk factors?
- Would a single blood thinner like rivaroxaban be a better option for me than combination therapy with aspirin, especially if my blood pressure is low?
- How often should I monitor my blood pressure at home to ensure it stays within a safe range?
This question is drawn from common patient questions about Cardiology and answered using cited medical research. We do not provide individualized advice.